Literature DB >> 29025878

Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.

Jennifer S Ten Kulve1, Dick J Veltman2, Victor E A Gerdes3, Liselotte van Bloemendaal4, Frederik Barkhof5, Carolyn F Deacon6, Jens J Holst6, Madeleine L Drent7, Michaela Diamant4, Richard G IJzerman4.   

Abstract

OBJECTIVE: It has been suggested that weight reduction and improvements in satiety after Roux-en-Y gastric bypass (RYGB) are partly mediated via postoperative neuroendocrine changes. Glucagon-like peptide-1 (GLP-1) is a gut hormone secreted after food ingestion and is associated with appetite and weight reduction, mediated via effects on the central nervous system (CNS). Secretion of GLP-1 is greatly enhanced after RYGB. We hypothesized that postoperative elevated GLP-1 levels contribute to the improved satiety regulation after RYGB via effects on the CNS. RESEARCH DESIGN AND METHODS: Effects of the GLP-1 receptor antagonist exendin 9-39 (Ex9-39) and placebo were assessed in 10 women before and after RYGB. We used functional MRI to investigate CNS activation in response to visual food cues (pictures) and gustatory food cues (consumption of chocolate milk), comparing results with Ex9-39 versus placebo before and after RYGB.
RESULTS: After RYGB, CNS activation was reduced in the rolandic operculum and caudate nucleus in response to viewing food pictures (P = 0.03) and in the insula in response to consumption of palatable food (P = 0.003). GLP-1 levels were significantly elevated postoperatively (P < 0.001). After RYGB, GLP-1 receptor blockade resulted in a larger increase in activation in the caudate nucleus in response to food pictures (P = 0.02) and in the insula in response to palatable food consumption (P = 0.002).
CONCLUSIONS: We conclude that the effects of RYGB on CNS activation in response to visual and gustatory food cues may be mediated by central effects of GLP-1. Our findings provide further insights into the mechanisms underlying the weight-lowering effects of RYGB.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29025878     DOI: 10.2337/dc16-2113

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  17 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  The Role of Glucagon-Like Peptide-1 in Energy Homeostasis.

Authors:  Marzieh Salehi; Jonathan Q Purnell
Journal:  Metab Syndr Relat Disord       Date:  2019-02-05       Impact factor: 1.894

Review 3.  A Role for GLP-1 in Treating Hyperphagia and Obesity.

Authors:  Harvey J Grill
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

4.  Obesity, body weight regulation and the brain: insights from fMRI.

Authors:  Janine M Makaronidis; Rachel L Batterham
Journal:  Br J Radiol       Date:  2018-02-16       Impact factor: 3.039

Review 5.  Strategies to Understand the Weight-Reduced State: Genetics and Brain Imaging.

Authors:  Ruth J F Loos; Charles Burant; Ellen A Schur
Journal:  Obesity (Silver Spring)       Date:  2021-04       Impact factor: 5.002

6.  The PYY/Y2R-Deficient Mouse Responds Normally to High-Fat Diet and Gastric Bypass Surgery.

Authors:  Brandon Boland; Michael B Mumphrey; Zheng Hao; Benji Gill; R Leigh Townsend; Sangho Yu; Heike Münzberg; Christopher D Morrison; James L Trevaskis; Hans-Rudolf Berthoud
Journal:  Nutrients       Date:  2019-03-10       Impact factor: 5.717

Review 7.  Metabolic and Endocrine Consequences of Bariatric Surgery.

Authors:  Isabel Cornejo-Pareja; Mercedes Clemente-Postigo; Francisco J Tinahones
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-19       Impact factor: 5.555

Review 8.  Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.

Authors:  Silvano Paternoster; Marco Falasca
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-11       Impact factor: 5.555

9.  Roux-en-Y Gastric Bypass in Obese Diabetic Rats Promotes Autophagy to Improve Lipid Metabolism through mTOR/p70S6K Signaling Pathway.

Authors:  Nanxi Ma; Rui Ma; Kaixin Tang; Xuesong Li; Bing He
Journal:  J Diabetes Res       Date:  2020-03-26       Impact factor: 4.011

10.  Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.

Authors:  Mojca Jensterle; Simona Ferjan; Tadej Battelino; Jernej Kovač; Saba Battelino; Dušan Šuput; Andrej Vovk; Andrej Janež
Journal:  Trials       Date:  2021-07-19       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.